BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 29542165)

  • 1. MAGI2 is an independent predictor of biochemical recurrence in prostate cancer.
    David SN; Arnold Egloff SA; Goyal R; Clark PE; Phillips S; Gellert LL; Hameed O; Giannico GA
    Prostate; 2018 Jun; 78(8):616-622. PubMed ID: 29542165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MAGI-2 in prostate cancer: an immunohistochemical study.
    Goldstein J; Borowsky AD; Goyal R; Roland JT; Arnold SA; Gellert LL; Clark PE; Hameed O; Giannico GA
    Hum Pathol; 2016 Jun; 52():83-91. PubMed ID: 26980016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of microvessel density in predicting recurrence in pathologic Stage T3 prostatic adenocarcinoma.
    Gettman MT; Pacelli A; Slezak J; Bergstralh EJ; Blute M; Zincke H; Bostwick DG
    Urology; 1999 Sep; 54(3):479-85. PubMed ID: 10475358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tertiary Gleason pattern 5 is a powerful predictor of biochemical relapse in patients with Gleason score 7 prostatic adenocarcinoma.
    Hattab EM; Koch MO; Eble JN; Lin H; Cheng L
    J Urol; 2006 May; 175(5):1695-9; discussion 1699. PubMed ID: 16600733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-grade prostatic intraepithelial neoplasia is an independent predictor of outcome after radical prostatectomy.
    Pierorazio PM; Lambert SM; Matsukhani M; Sprenkle PC; McCann TR; Katz AE; Olsson CA; Benson MC; McKiernan JM
    BJU Int; 2007 Nov; 100(5):1066-70. PubMed ID: 17784880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative study of immunohistochemical expression of ERG and MAGI2 in prostatic carcinoma.
    Dawoud MM; Aiad HA; Bahbah AMNH; Shaban MI
    Ann Diagn Pathol; 2021 Jun; 52():151727. PubMed ID: 33713943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
    Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
    J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of high-grade prostatic intraepithelial neoplasia for biochemical relapse of prostate carcinoma after radical prostatectomy.
    Auskalnis S; Milonas D; Jievaltas M; Vaiciūnas K; Mickevicius A; Gudinaviciene I
    Medicina (Kaunas); 2010; 46(9):604-10. PubMed ID: 21252594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relationship between the extent of surgical margin positivity and prostate specific antigen recurrence in radical prostatectomy specimens.
    Marks RA; Koch MO; Lopez-Beltran A; Montironi R; Juliar BE; Cheng L
    Hum Pathol; 2007 Aug; 38(8):1207-11. PubMed ID: 17490720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer.
    Bañez LL; Sun L; van Leenders GJ; Wheeler TM; Bangma CH; Freedland SJ; Ittmann MM; Lark AL; Madden JF; Hartman A; Weiss G; Castaños-Vélez E
    J Urol; 2010 Jul; 184(1):149-56. PubMed ID: 20478579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Presence or absence of a positive pathological margin outperforms any other margin-associated variable in predicting clinically relevant biochemical recurrence in Gleason 7 prostate cancer.
    Huang JG; Pedersen J; Hong MK; Harewood LM; Peters J; Costello AJ; Hovens CM; Corcoran NM
    BJU Int; 2013 May; 111(6):921-7. PubMed ID: 23350712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database.
    Mithal P; Howard LE; Aronson WJ; Kane CJ; Cooperberg MR; Terris MK; Amling CL; Freedland SJ
    Int J Urol; 2015 Apr; 22(4):362-6. PubMed ID: 25728968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of Cdc20 in clinically localized prostate cancer: Relation to high Gleason score and biochemical recurrence after laparoscopic radical prostatectomy.
    Mao Y; Li K; Lu L; Si-Tu J; Lu M; Gao X
    Cancer Biomark; 2016; 16(3):351-8. PubMed ID: 26889981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer.
    Lee CT; Capodieci P; Osman I; Fazzari M; Ferrara J; Scher HI; Cordon-Cardo C
    Clin Cancer Res; 1999 May; 5(5):977-83. PubMed ID: 10353729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical features and prognosis of prostate cancer with high-grade prostatic intraepithelial neoplasia.
    Lee D; Lee C; Kwon T; You D; Jeong IG; Hong JH; Ahn H; Kim CS
    Korean J Urol; 2015 Aug; 56(8):565-71. PubMed ID: 26279825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The significance of monoamine oxidase-A expression in high grade prostate cancer.
    Peehl DM; Coram M; Khine H; Reese S; Nolley R; Zhao H
    J Urol; 2008 Nov; 180(5):2206-11. PubMed ID: 18804811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative prediction of small volume cancer (less than 0.5 ml) in radical prostatectomy specimens.
    Cheng L; Poulos CK; Pan CX; Jones TD; Daggy JK; Eble JN; Koch MO
    J Urol; 2005 Sep; 174(3):898-902. PubMed ID: 16093983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of interphase fluorescence in situ hybridization in prostate needle biopsy specimens with isolated high-grade prostatic intraepithelial neoplasia as a predictor of prostate adenocarcinoma on follow-up biopsy.
    Bastacky S; Cieply K; Sherer C; Dhir R; Epstein JI
    Hum Pathol; 2004 Mar; 35(3):281-9. PubMed ID: 15017583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Visual estimation of tumour extent is not an independent predictor of prostate specific antigen recurrence.
    Jones TD; Koch MO; Lin H; Cheng L
    BJU Int; 2005 Dec; 96(9):1253-7. PubMed ID: 16287440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.